Baseline 6-min walk distance predicts survival in lung transplant candidates

American Journal of Transplantation

Volumn 8, Issue 7, 2008, Pages 1498-1505

  Martinu, T ^a   Babyak, M A ^a   O'Connell, C F ^a   Carney, R M ^b   Trulock, E P ^c   Davis, R D ^a   Blumenthal, J A ^a   Palmer, S M ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Exercise capacity; Exercise testing; Lung; Lung transplantation; Posttransplantation; Pretransplant; Prognosis; Prognostic factors survival; Survival analysis

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; WALKING;

ADULT; AGED; EXERCISE TEST; FEMALE; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; SURVIVAL RATE; WAITING LISTS; WALKING;

EID: 47249113434     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2008.02264.x     Document Type: Article

References (25)

1. ATS statement: Guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002 166: 111 117.
2. Miyamoto S, Nagaya N, Satoh T et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000 161 (2 Pt 1 487 492.
3. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The primary pulmonary hypertension study group. N Engl J Med 1996 334: 296 302.
4. Celli BR, Cote CG, Marin JM et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004 350: 1005 1012.
5. Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006 174: 659 664.
6. Erbes R, Schaberg T, Loddenkemper R. Lung function tests in patients with idiopathic pulmonary fibrosis. Are they helpful for predicting outcome? Chest 1997 111: 51 57.
7. Miki K, Maekura R, Hiraga T et al. Impairments and prognostic factors for survival in patients with idiopathic pulmonary fibrosis. Respir Med 2003 97: 482 490.
8. Gay SE, Kazerooni EA, Toews GB et al. Idiopathic pulmonary fibrosis: Predicting response to therapy and survival. Am J Respir Crit Care Med 1998 157 (4 Pt 1 1063 1072.
9. Vizza CD, Yusen RD, Lynch JP, Fedele F, Alexander Patterson G, Trulock EP. Outcome of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2000 162 (3 Pt 1 819 825.
10. Sharples L, Hathaway T, Dennis C, Caine N, Higenbottam T, Wallwork J. Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation. J Heart Lung Transplant 1993 12: 669 674.
11. Blumenthal JA, Babyak MA, Keefe FJ et al. Telephone-based coping skills training for patients awaiting lung transplantation. J Consult Clin Psychol 2006 74: 535 544.
12. Maurer JR, Frost AE, Estenne M, Higenbottam T, Glanville AR. International guidelines for the selection of lung transplant candidates. The International Society for Heart and Lung Transplantation, the American Thoracic Society, the American Society of Transplant Physicians, the European Respiratory Society. J Heart Lung Transplant 1998 17: 703 709.
13. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981 123: 659 664.
14. Harrell FE. Regression Modeling Strategies: With Applications To Linear Models, Logistic Regression, and Survival Analysis. New York: Springer 2001: 74 75.
15. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer 2000: 74 75.
16. Hollander N, Sauerbrei W, Schumacher M. Confidence intervals for the effect of a prognostic factor after selection of an 'optimal' cutpoint. Stat Med 2004 23: 1701 1713.
17. Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using "optimal" cutpoints in the evaluation of prognostic factors. J Natl Cancer Inst 1994 86: 829 835.
18. Schulgen G, Lausen B, Olsen JH, Schumacher M. Outcome-oriented cutpoints in analysis of quantitative exposures. Am J Epidemiol 1994 140: 172 184.
19. Flaherty KR, Andrei AC, Murray S et al. Idiopathic pulmonary fibrosis: Prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006 174: 803 809.
20. Hosenpud JD, Bennett LE, Keck BM, Edwards EB, Novick RJ. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998 351: 24 27.
21. Charman SC, Sharples LD, McNeil KD, Wallwork J. Assessment of survival benefit after lung transplantation by patient diagnosis. J Heart Lung Transplant 2002 21: 226 232.
22. De Meester J, Smits JM, Persijn GG, Haverich A. Listing for lung transplantation: Life expectancy and transplant effect, stratified by type of end-stage lung disease, the Eurotransplant experience. J Heart Lung Transplant 2001 20: 518 524.
23. Thabut G, Mal H, Castier Y et al. Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis. J Thorac Cardiovasc Surg 2003 126: 469 475.
24. Geertsma A, Ten Vergert EM, Bonsel GJ, de Boer WJ, Van Der Bij W. Does lung transplantation prolong life? A comparison of survival with and without transplantation. J Heart Lung Transplant 1998 17: 511 516.
25. UNOS website. Available at http://wwwunosorg/SharedContent-Documents/ Calculation_Guide.pdf.